SCHEMBL2912462

SCHEMBL2912462

O=C(O)Cc1cccc(N2CCC3(CC2)C(=O)N(CC2CCCC2)C(=O)N3CCc2ccc(Cl)cc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 1/20 0.41
CCR3 P51677 1/20 0.41
KCNH2 Q12809 1/20 0.41
CNR1 P21554 4/20 0.41
ITGB3 P05106 2/20 0.40
ITGA2B P08514 2/20 0.40
SIGMAR1 Q99720 2/20 0.37
CCR5 P51681 1/20 0.35
PPARA Q07869 1/20 0.35
CNR2 P34972 1/20 0.34
TP53 P04637 1/20 0.34
MDM2 Q00987 1/20 0.34
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
SLC6A4 P31645 1/20 0.34
MCHR1 Q99705 1/20 0.34
HSD11B1 P28845 2/20 0.34
FFAR4 Q5NUL3 1/20 0.34
KCNQ2 O43526 1/20 0.34
OPRM1 P35372 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2917649 0.91 HRH1 (0.41) HRH1CCR3KCNH2CNR1ITGB3
SCHEMBL13849471 0.90 FFAR4 (0.39) HRH1CCR3KCNH2CNR1ITGB3
SCHEMBL2915979 0.90 HRH1 (0.41) HRH1CCR3KCNH2CNR1ITGB3
SCHEMBL2910510 0.90 SIGMAR1 (0.38) HRH1CCR3KCNH2CNR1ITGB3
SCHEMBL2917231 0.89 HRH1 (0.41) HRH1CCR3KCNH2CNR1ITGB3
SCHEMBL2915435 0.88 SIGMAR1 (0.38) HRH1CCR3KCNH2ITGB3ITGA2B
SCHEMBL2917453 0.88 FFAR4 (0.42) HRH1CCR3KCNH2ITGB3ITGA2B
SCHEMBL2912597 0.86 FFAR4 (0.43) HRH1CCR3KCNH2ITGB3ITGA2B
SCHEMBL13849472 0.86 ITGB3 (0.37) HRH1CCR3KCNH2CNR1ITGB3
SCHEMBL13212985 0.85 ITGB3 (0.42) HRH1CCR3KCNH2CNR1ITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979355-B1 SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2010-08-18 EP claimed
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2009-05-28 US claimed
EP-1979355-A1 SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2008-10-15 EP claimed
WO-2007087448-A1 SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2007-08-02 WO claimed
EP-1979355-B1 SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2010-08-18 EP disclosed
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2009-05-28 US disclosed
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2009-05-28 US disclosed
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS PPARD, PPARG, PPARA HRH1 3688/4885CCR3 1444/4885KCNH2 3975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.